Vaccine for AIDS and Ebola virus infection

Virus Research

Volumn 92, Issue 2, 2003, Pages 213-217

  Nabel, Gary J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

AIDS; Ebola virus; Filovirus; Hemorrhagic fever; HIV; Immunodeficiency

Indexed keywords

DNA VACCINE; EBOLA VACCINE; GAG PROTEIN; GLYCOPROTEIN GP 140; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; PLASMID DNA; POL PROTEIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY RESPONSE; CONFERENCE PAPER; DNA VECTOR; DRUG EFFICACY; DRUG POTENCY; EBOLA VIRUS; EXPERIMENTAL MODEL; GUINEA PIG; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGY; MOLECULAR GENETICS; NONHUMAN; PATHOGENESIS; PRIMATE; PRIORITY JOURNAL; RODENT; VIROLOGY; VIRUS HEMORRHAGIC FEVER; VIRUS IMMUNITY;

ANIMALIA; CAVIA PORCELLUS; EBOLA VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; MARBURG-LIKE VIRUSES; PRIMATES; RNA VIRUSES; RODENTIA; SUS SCROFA;

EID: 0037383295     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-1702(02)00354-4     Document Type: Conference Paper

References (27)

1. Balter M. Emerging diseases. On the trail of Ebola and Marburg viruses. Science. 290:2000;923-925.
2. Chakrabarti B.K., Kong W.P., Wu B.Y., Yang Z.Y., Friborg J., Ling X., King S.R., Montefiori D.C., Nabel G.J. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J. Virol. 76:2002;5357-5368.
3. Chan D.C., Fass D., Berger J.M., Kim P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell. 89:1997;263-273.
4. Colebunders R., Borchert M. Ebola haemorrhagic fever - a review. J. Infect. 40:2000;16-20.
5. Donnelly J.J., Ulmer J.B., Shiver J.W., Liu M.A. DNA vaccines. Annu. Rev. Immunol. 15:1997;617-648.
6. Eckert D.M., Malashkevich V.N., Hong L.H., Carr P.A., Kim P.S. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell. 99:1999;103-115.
7. Huang Y., Kong W.P., Nabel G.J. Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J. Virol. 75:2001;4947-4951.
8. Kilby J.M., Hopkins S., Venetta T.M., DiMassimo B., Cloud G.A., Lee J.Y., Alldredge L., Hunter E., Lambert D., Bolognesi D., Matthews T., Johnson M.R., Nowak M.A., Shaw G.M., Saag M.S. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4:1998;1302-1307.
9. Kwong P.D., Wyatt R., Majeed S., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure Fold Des. 8:2000;1329-1339.
10. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 393:1998;648-659.
11. Nabel G.J. Challenges and opportunities for development of an AIDS vaccine. Nature. 410:2001;1002-1007.
12. Nabel G.J. HIV vaccine strategies. Vaccine. 20:2002;1945-1947.
13. Peters C.J., Sanchez A., Rollin P.E., Ksiazek T.G., Murphy F.A. Fields B.N., Knipe D.M., Howley P.M. Fields Virology. 1996;1161-1176 Lippincott-Raven, Philadelphia.
14. Peters C.J., Khan A.S. Klenk H.-D. Current Topics in Microbiology and Immunology. 235:1999;85-95 Springer, Berlin.
15. Pinto L.A., Sullivan J., Berzofsky J.A., Clerici M., Kessler H.A., Landay A.L., Shearer G.M. ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J. Clin. Invest. 96:1995;867-876.
16. Rowland-Jones S.L., Dong T., Fowke K.R., Kimani J., Krausa P., Newell H., Blanchard T., Ariyoshi K., Oyugi J., Ngugi E., Bwayo J., MacDonald K.S., McMichael A.J., Plummer F.A. Cytotoxic T cell response to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Invest. 102:1998;1758-1765.
17. Saag M.S., Hahn B.H., Gibbons J., Li Y., Parks E.S., Parks W.P., Shaw G.M. Extensive variation of human immunodeficiency virus type-1 in vivo. Nature. 334:1988;440-444.
18. Sanchez A., Trappier S.G., Mahy B.W., Peters C.J., Nichol S.T. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc. Natl. Acad. Sci. USA. 93:1996;3602-3607.
19. Sullivan N.J., Sanchez A., Rollin P.E., Yang Z.Y., Nabel G.J. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 408:2000;605-609.
20. Tighe H., Corr M., Roman M., Raz E. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol. Today. 19:1998;89-97.
21. Volchkov V.E., Becker S., Volchkova V.A., Ternovoj V.A., Kotov A.N., Netesov S.V., Klenk H.D. GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology. 214:1995;421-430.
22. Weissenhorn W., Dessen A., Harrison S.C., Skehel J.J., Wiley D.C. Atomic structure of the ectodomain from HIV-1 gp41. Nature. 387:1997;426-430. see comments.
23. Wyatt R., Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science. 280:1998;1884-1888.
24. Xu L., Sanchez A., Yang Z., Zaki S.R., Nabel E.G., Nichol S.T., Nabel G.J. Immunization for Ebola virus infection. Nat. Med. 4:1998;37-42.
25. Yang Z., Delgado R., Xu L., Todd R.F., Nabel E.G., Sanchez A., Nabel G.J. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science. 279:1998;1034-1037.
26. Yang Z.Y., Duckers H.J., Sullivan N.J., Sanchez A., Nabel E.G., Nabel G.J. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat. Med. 8:2000;886-889.
27. Zinkernagel R.M., Doherty P.C. Major transplantation antigens, viruses, and specificity of surveillance T cells. Contemp. Top. Immunobiol. 7:1977;179-220.